The pharmacological management of metabolic syndrome

References

• Sarafidis PA, Nilsson PM. The metabolic syndrome: a glance at its history. J Hypertens. 2006;24:621–626.
   PubMed Web of Science ®Google Scholar
• Dawber TR, Meadors GF, Moore FE JR. Epidemiological approaches to heart disease: the Framingham study. Am J Public Health Nations Health. 1951;41:279–281.
   PubMed Web of Science ®Google Scholar
• Wilson PW, D’Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–1847.
   PubMed Web of Science ®Google Scholar
• Eckel RH, Alberti KG, Grundy SM, et al. The metabolic syndrome. Lancet. 2010;375:181–183.
   PubMed Web of Science ®Google Scholar
• Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract. 2014;2014:943162:1–21.
   Google Scholar
• Stern MP, Haffner SM. Body fat distribution and hyperinsulinemia as risk factors for diabetes and cardiovascular disease. Arteriosclerosis. 1986;6:123–130.
   PubMedGoogle Scholar
• Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–1607.
   PubMed Web of Science ®Google Scholar
• Benedict M, Zhang X. Non-alcoholic fatty liver disease: an expanded review. World J Hepatol. 2017;9:715–732.
   PubMed Web of Science ®Google Scholar
• Patil R, Sood GK. Non-alcoholic fatty liver disease and cardiovascular risk. World J Gastrointest Pathophysiol. 2017;8:51–58.
   PubMedGoogle Scholar
• Uzunlulu M, Telci CO, Oguz A. Association between metabolic syndrome and cancer. Ann Nutr Metab. 2016;68:173–179.
   PubMed Web of Science ®Google Scholar
• Delitala AP, Capobianco G, Delitala G, et al. Polycystic ovary syndrome, adipose tissue and metabolic syndrome. Arch Gynecol Obstet. 2017;296:405–419.
   PubMed Web of Science ®Google Scholar
• Koren D, Dumin M, Gozal D. Role of sleep quality in the metabolic syndrome. Diabetes Metab Syndr Obes. 2016;9:281–310.
   PubMed Web of Science ®Google Scholar
• Shabanzadeh DM, Sorensen LT, Jorgensen T. Determinants for gallstone formation - a new data cohort study and a systematic review with meta-analysis. Scand J Gastroenterol. 2016;51:1239–1248.
   PubMed Web of Science ®Google Scholar
• Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am. 2004;33:351–375.
   PubMed Web of Science ®Google Scholar
• Faienza MF, Wang DQ, Frühbeck G, et al. The dangerous link between childhood and adulthood predictors of obesity and metabolic syndrome. Intern Emerg Med. 2016;11:175–182.
   PubMed Web of Science ®Google Scholar
• Miller EL, Mitchell A. Metabolic syndrome: screening, diagnosis, and management. J Midwifery Womens Health. 2006;51:141–151.
   PubMed Web of Science ®Google Scholar
• Xu Y, Shen S, Sun L, et al. Metabolic syndrome risk after gestational diabetes: a systematic review and meta-analysis. PLoS One. 2014;9:e87863.
   PubMed Web of Science ®Google Scholar
• De Hert M, Schreurs V, Vancampfort D, et al. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry. 2009;8:15–22.
   PubMed Web of Science ®Google Scholar
• De Hert M, Correll CU, Bobes J, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011;10:52–77.
   PubMed Web of Science ®Google Scholar
• De Hert M, Bobes J, Cetkovich-Bakmas M, et al. Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, and recommendations at the system and individual level. World Psychiatry. 2011;10:138–151.
   PubMed Web of Science ®Google Scholar
• Manu P, Dima L, Shulman M, et al. Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management. Acta Psychiatr Scand. 2015;132:97–108.
   PubMed Web of Science ®Google Scholar
• Ifteni P, Moga MA, Burtea V, et al. Schizophrenia relapse after stopping olanzapine treatment during pregnancy: a case report. Ther Clin Risk Manag. 2014;10:901–904.
   PubMed Web of Science ®Google Scholar
• Correll CU, Solmi M, Veronese N, et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry. 2017;16:163–180.
   PubMed Web of Science ®Google Scholar
• Stubbs B, Koyanagi A, Veronese N, et al. Physical multimorbidity and psychosis: comprehensive cross sectional analysis including 242,952 people across 48 low- and middle-income countries. BMC Med. 2016;14:189.
   PubMed Web of Science ®Google Scholar
• Vancampfort D, Correll CU, Galling B, et al. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. World Psychiatry. 2016;15(2):166–174.
   PubMed Web of Science ®Google Scholar
• Vancampfort D, Stubbs B, Mitchell AJ, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry. 2015;14:339–347.
   PubMed Web of Science ®Google Scholar
• Correll CU, Detraux J, De Lepeleire J, et al. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015;14:119–136.
   PubMed Web of Science ®Google Scholar
• Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–1645.
   PubMed Web of Science ®Google Scholar
• Alberti KG, Zimmet P, Shaw J. The metabolic syndrome-a new worldwide definition. Lancet. 2005;366:1059–1062.
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer FX. The obesity epidemic: pathophysiology and consequences of obesity. Obes Res. 2002;10(Suppl 2):97S–104S.
   PubMedGoogle Scholar
• Smith U, Kahn BB. Adipose tissue regulates insulin sensitivity: role of adipogenesis, de novo lipogenesis and novel lipids. J Intern Med. 2016;280:465–475.
   PubMed Web of Science ®Google Scholar
• Neeland IJ, Turer AT, Ayers CR, et al. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA. 2012;308:1150–1159.
   PubMed Web of Science ®Google Scholar
• Banerji MA, Lebowitz J, Chaiken RL, et al. Relationship of visceral adipose tissue and glucose disposal is independent of sex in black NIDDM subjects. Am J Physiol. 1997;273:E425–32.
   PubMed Web of Science ®Google Scholar
• Kahn SE, Cooper ME, Del PS. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014;383:1068–1083.
   PubMed Web of Science ®Google Scholar
• Nathan DM. Diabetes: advances in diagnosis and treatment. JAMA. 2015;314:1052–1062.
   PubMed Web of Science ®Google Scholar
• Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10:330–344.
   PubMed Web of Science ®Google Scholar
• Olefsky JM, Farquhar JW, Reaven GM. Reappraisal of the role of insulin in hypertriglyceridemia. Am J Med. 1974;57:551–560.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Obesity management for the treatment of type 2 diabetes. Diabetes Care. 2017;40:S57–63.
   PubMedGoogle Scholar
• Esser N, Legrand-Poels S, Piette J, et al. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract. 2014;105:141–150.
   PubMed Web of Science ®Google Scholar
• Blokhin IO, Lentz SR. Mechanisms of thrombosis in obesity. Curr Opin Hematol. 2013;20:437–444.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003;107:391–397.
   PubMed Web of Science ®Google Scholar
• Colotta F, Jansson B, Bonelli F. Modulation of inflammatory and immune responses by vitamin D. J Autoimmun. 2017 cited 2017 Oct;85:78–97. pii: S0896-8411(17)30463-8 DOI:10.1016/j.jaut.2017.07.007
   PubMed Web of Science ®Google Scholar
• Reis JP, Von MD, Miller ER III, et al. Vitamin D status and cardiometabolic risk factors in the United States adolescent population. Pediatrics. 2009;124:e371–9.
   PubMed Web of Science ®Google Scholar
• Stancakova A, Laakso M. Genetics of metabolic syndrome. Rev Endocr Metab Disord. 2014;15:243–252.
   PubMed Web of Science ®Google Scholar
• Kristiansson K, Perola M, Tikkanen E, et al. Genome-wide screen for metabolic syndrome susceptibility Loci reveals strong lipid gene contribution but no evidence for common genetic basis for clustering of metabolic syndrome traits. Circ Cardiovasc Genet. 2012;5:242–249.
   PubMed Web of Science ®Google Scholar
• Stirnadel H, Lin X, Ling H, et al. Genetic and phenotypic architecture of metabolic syndrome-associated components in dyslipidemic and normolipidemic subjects: the GEMS study. Atherosclerosis. 2008;197:868–876.
   PubMed Web of Science ®Google Scholar
• Park YW, Zhu S, Palaniappan L, et al. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the third National Health and Nutrition Examination Survey, 1988–1994. Arch Intern Med. 2003;163:427–436.
   PubMed Web of Science ®Google Scholar
• Ogden CL, Carroll MD, Fryar CD, et al. Prevalence of obesity among adults and youth: United States, 2011–2014. NCHS Data Brief. 2015;219:1–8.
   Google Scholar
• Mozumdar A, Liguori G. Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999–2006. Diabetes Care. 2011;34:216–219.
   PubMed Web of Science ®Google Scholar
• Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356–359.
   PubMed Web of Science ®Google Scholar
• Kahn R, Buse J, Ferrannini E, et al. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the study of diabetes. Diabetes Care. 2005;28:2289–2304.
   PubMed Web of Science ®Google Scholar
• Straker D, Correll CU, Kramer-Ginsberg E, et al. Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications. Am J Psychiatry. 2005;162:1217–1221.
   PubMed Web of Science ®Google Scholar
• Reaven GM. The metabolic syndrome: is this diagnosis necessary? Am J Clin Nutr. 2006;83:1237–1247.
   PubMed Web of Science ®Google Scholar
• Lam DW, Leroith D. Metabolic syndrome. In: De Groot LJ, Chrousos G, Dungan K, editors. Endotext. South Dartmouth(MA): MDText.com,Inc.; 2000. Available from: https://www.ncbi.nlm.nih.gov/books/NBK278936/
   Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285:2486–2497.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, lung, and blood institute scientific statement: executive summary. Crit Pathw Cardiol. 2005;4:198–203.
   PubMedGoogle Scholar
• Stone NJ, Robinson JG, Lichtenstein AH, et al. American College of Cardiology/American Heart Association task force on practice guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. Circulation. 2014;129:S1–45.
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. Focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology task force on expert consensus decision pathways. J Am Coll Cardiol. 2017;2017(70):1785–1822.
   Google Scholar
• Sun K, Liu J, Ning G. Active smoking and risk of metabolic syndrome: a meta-analysis of prospective studies. PLoS One. 2012;7:e47791.
   PubMed Web of Science ®Google Scholar
• Batsis JA, Romero-Corral A, Collazo-Clavell ML, et al. Effect of bariatric surgery on the metabolic syndrome: a population-based, long-term controlled study. Mayo Clin Proc. 2008;83:897–907.
   PubMed Web of Science ®Google Scholar
• Rogozea L, Purcaru D, Leaşu F, et al. Biomedical research - opportunities and ethical challenges. Rom J Morphol Embryol. 2014;55:719–722.
   PubMed Web of Science ®Google Scholar
• Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;CD004816. DOI:10.1002/14651858.CD004816.pub5
   PubMed Web of Science ®Google Scholar
• Janke J, Schupp M, Engeli S, et al. Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-gamma activation. J Hypertens. 2006;24:1809–1816.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322.
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–1844.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–657.
   PubMed Web of Science ®Google Scholar
• Owen JG, Reisin E. Anti-hypertensive drug treatment of patients with and the metabolic syndrome and obesity: a review of evidence, meta-analysis, post hoc and guidelines publications. Curr Hypertens Rep. 2015;17:558.
   PubMed Web of Science ®Google Scholar
• Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med. 1988;319:24–33.
   PubMed Web of Science ®Google Scholar
• Manu P, Rogozea L. The discovery of statins. Am J Ther. 2016;23(4):e980–1.
   PubMed Web of Science ®Google Scholar
• Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell. 1997;89:331–340.
   PubMed Web of Science ®Google Scholar
• Sadowitz B, Maier KG, Gahtan V. Basic science review: statin therapy—part I: thepleiotropic effects of statins in cardiovasculardisease. Vasc Endovasc Surg. 2010;44:241–251.
   PubMed Web of Science ®Google Scholar
• Giner-Galvañ V, Esteban-Giner MJ, Pallarés-Carratalá V. Overview of guidelines for the management of dyslipidemia: EU perspectives. Vasc Health Risk Manag. 2016;12:357–369.
   PubMed Web of Science ®Google Scholar
• Stalenhoef AF, Ballantyne CM, Sarti C, et al. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study. Eur Heart J. 2005;26:2664–2672.
   PubMed Web of Science ®Google Scholar
• Barter PJ, Brandrup-Wognsen G, Palmer MK, et al. Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER database. J Lipid Res. 2010;51:1546–1553.
   PubMed Web of Science ®Google Scholar
• Chang Y, Robidoux J. Dyslipidemia management update. Curr Opin Pharmacol. 2017;33:47–55.
   PubMed Web of Science ®Google Scholar
• Sugizaki T, Watanabe M, Horai Y, et al. The Niemann-Pick C1 like 1 (NPC1L1) inhibitor ezetimibe improves metabolic disease via decreased liver X receptor (LXR) activity in liver of obese male mice. Endocrinology. 2014;155:2810–2819.
   PubMed Web of Science ®Google Scholar
• Catapano AL, Graham I, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias. Atherosclerosis. 2016;2016(253):281–344.
   Google Scholar
• Cannon CP, Blazing MA, Giugliano RP, et al. IMPROVE-IT investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–2397.
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology task force on clinical expert consensus documents. J Am Coll Cardiol. 2016;2016(68):92–125.
   Web of Science ®Google Scholar
• Ooi CP, Loke SC. Colesevelam for type 2 diabetes mellitus: an abridged cochrane review. Diabet Med. 2014;31:2–14.
   PubMed Web of Science ®Google Scholar
• Abifadel M, Varret M, Rabès JP. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34:154–156.
   PubMed Web of Science ®Google Scholar
• Schmidt AF, Pearce LS, Wilkins JT, et al. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2017;4:CD011748.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–1722.
   PubMed Web of Science ®Google Scholar
• Lukasova M, Hanson J, Tunaru S, et al. Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials. Trends Pharmacol Sci. 2011;32:700–707.
   PubMed Web of Science ®Google Scholar
• Shepherd J, Betteridge J, Van GL. Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. Curr Med Res Opin. 2005;21:665–682.
   PubMed Web of Science ®Google Scholar
• HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, Hopewell JC, et al. Effects of extended release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371:203–212.
   PubMed Web of Science ®Google Scholar
• Schandelmaier S, Briel M, Saccilotto R, et al. Niacin for primary and secondary prevention of cardiovascular events. Cochrane Database Syst Rev. 2017;6:CD009744.
   PubMedGoogle Scholar
• Wang D, Liu B, Tao W, et al. Fibrates for secondary prevention of cardiovascular disease and stroke. Cochrane Database Syst Rev. 2015;CD009580. DOI:10.1002/14651858.CD009580.pub2
   PubMedGoogle Scholar
• Bangalore S, Fakheri R, Toklu B, et al. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients without heart failure? Insights from 254,301 patients from randomized trials. Mayo Clin Proc. 2016;91:51–60.
   PubMed Web of Science ®Google Scholar
• Kraja AT, Province MA, Straka RJ, et al. Fenofibrate and metabolic syndrome. Endocr Metab Immune Disord Drug Targets. 2010;10:138–148.
   PubMedGoogle Scholar
• Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849–1861.
   PubMed Web of Science ®Google Scholar
• Keene D, Price C, Shun-Shin MJ, et al. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysisof randomised controlled trials including 117,411 patients. Bmj. 2014;349:g4379.
   PubMed Web of Science ®Google Scholar
• Ip CK, Jin DM, Gao JJ, et al. Effects of add-on lipid-modifying therapy on top of background statin treatment on major cardiovascular events: a meta-analysis of randomized controlled trials. Int J Cardiol. 2015;191:138–148.
   PubMed Web of Science ®Google Scholar
• Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010;375:1875–1884.
   PubMed Web of Science ®Google Scholar
• Lee M, Saver JL, Towfighi A, et al. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. Atherosclerosis. 2011;217:492–498.
   PubMed Web of Science ®Google Scholar
• Bruckert E, Labreuche J, Deplanque D, et al. Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis. J Cardiovasc Pharmacol. 2011;57:267–272.
   PubMed Web of Science ®Google Scholar
• Ginsberg HN, Elam MB, Lovato LC, et al.; ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563–1574.
   PubMed Web of Science ®Google Scholar
• Mansour M. The roles of peroxisome proliferator-activated receptors in the metabolic syndrome. Prog Mol Biol Transl Sci. 2014;121:217–266.
   PubMed Web of Science ®Google Scholar
• Karalis DG. A review of clinical practice guidelines for the management of hypertriglyceridemia: a focus on high dose omega-3 fatty acids. Adv Ther. 2017;34:300–323.
   PubMed Web of Science ®Google Scholar
• Musini VM, Gueyffier F, Puil L, et al. Pharmacotherapy for hypertension in adults aged 18 to 59 years. Cochrane Database Syst Rev. 2017;8:CD008276.
   PubMedGoogle Scholar
• Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database Syst Rev. 2009;3:CD001841.
   PubMed Web of Science ®Google Scholar
• Gress TW, Nieto FJ, Shahar E, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med. 2000;342:905–912.
   PubMed Web of Science ®Google Scholar
• The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–2997.
   PubMed Web of Science ®Google Scholar
• Fergus IV, Connell KL, Ferdinand KC. A comparison of vasodilating and non-vasodilating beta-blockers and their effects on cardiometabolic risk. Curr Cardiol Rep. 2015;17:38.
   PubMed Web of Science ®Google Scholar
• Koh KK, Han SH, Oh PC, et al. Combination therapy for treatment or prevention of atherosclerosis: focus on the lipid-RAAS interaction. Atherosclerosis. 2010;209:307–313.
   PubMed Web of Science ®Google Scholar
• Yamada S. Pleiotropic effects of ARB in metabolic syndrome. Curr Vasc Pharmacol. 2011;9:158–161.
   PubMed Web of Science ®Google Scholar
• Kintscher U, Bramlage P, Paar WD, et al. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the treat to target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc Diabetol. 2007;6:12.
   PubMed Web of Science ®Google Scholar
• Bavishi C, Bangalore S, Messerli FH. Renin angiotensin aldosterone system inhibitors in hypertension: is there evidence for benefit independent of blood pressure reduction? Prog Cardiovasc Dis. 2016;59:253–261.
   PubMed Web of Science ®Google Scholar
• Strauss MH, Hall AS. The divergent cardiovascular effects of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on myocardial infarction and death. Prog Cardiovasc Dis. 2016;58:473–482.
   PubMed Web of Science ®Google Scholar
• Cheng J, Zhang W, Zhang X, et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med. 2014;174:773–785.
   PubMed Web of Science ®Google Scholar
• Bangalore S, Fakheri R, Toklu B, et al. Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematicreview and meta-analysis of randomized trials [published correction appears in BMJ. BMJ. 2016;352: i438. 2016;352:i1525.
   PubMed Web of Science ®Google Scholar
• Palmer SC, Mavridis D, Navarese E, et al. Comparative efficacy and safety of blood pressure lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet. 2015;385:2047–2056.
   PubMed Web of Science ®Google Scholar
• Remonti LR, Dias S, Leitão CB, et al. Classes of antihypertensive agents and mortality in hypertensive patients with type 2 diabetes network meta-analysis of randomized trials. J Diabetes Complications. 2016;30:1192–1200.
   PubMed Web of Science ®Google Scholar
• Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2017 executive summary. Endocr Pract. 2017;23:207–238.
   PubMed Web of Science ®Google Scholar
• Yamagishi S. Cardiovascular disease in recent onset diabetes mellitus. J Cardiol. 2011;57:257–262.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Approaches to glycemic treatment. Diabetes Care. 2016;39(Suppl 1):S52–S59.
   PubMedGoogle Scholar
• Orchard TJ, Temprosa M, Goldberg R, et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med. 2005;142:611–619.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–865.
   PubMed Web of Science ®Google Scholar
• Griffin SJ, Leaver JK, Irving GJ. Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. Diabetologia. 2017;60:1620–1629.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–2471.
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–1326.
   PubMed Web of Science ®Google Scholar
• White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–1335.
   PubMed Web of Science ®Google Scholar
• Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232–242.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–2257.
   PubMed Web of Science ®Google Scholar
• Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377:1228–1239.
   PubMed Web of Science ®Google Scholar
• Perreault L, Færch K, Gregg EW. Can cardiovascular epidemiology and clinical trials close the risk management gap between diabetes and prediabetes? Curr Diab Rep. 17. 2017;77. DOI:10.1007/s11892-017-0899-7
   PubMed Web of Science ®Google Scholar
• Li G, Zhang P, Wang J, et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the da Qing diabetes prevention study: a 23-year follow-up study. Lancet Diabetes Endocrinol. 2014;2:474–480.
   PubMed Web of Science ®Google Scholar
• Kernan WN, Viscoli CM, Furie KL, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016;374:1321–1331.
   PubMed Web of Science ®Google Scholar
• Patel D. Pharmacotherapy for the management of obesity. Metabolism. 2015;64:1376–1385.
   PubMed Web of Science ®Google Scholar
• Wang ZJ, Zhou YJ, Galper BZ, et al. Association of body mass index with mortality and cardiovascular events for patients with coronary artery disease: a systematic review and meta-analysis. Heart. 2015;101:1631–1638.
   PubMed Web of Science ®Google Scholar
• Nuffer WA, Trujillo JM. Liraglutide: a new option for the treatment of obesity. Pharmacotherapy. 2015;35:926–934.
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373:11–22.
   PubMed Web of Science ®Google Scholar
• Jakob T, Nordmann AJ, Schandelmaier S, et al. Fibrates for primary prevention of cardiovascular disease events. Cochrane Database Syst Rev. 2016;(11):CD009753. DOI:10.1002/14651858.CD009753.pub2
   PubMed Web of Science ®Google Scholar